Compare Carvana Co (CVNA) vs Eli Lilly And Co (LLY) Price & Performance

Carvana (CVNA) trades at $63.21, up 0.72% with strong fundamental momentum including 10 consecutive quarters of record profitability. Revenue surged 52% in Q2 FY26 to $20.32B annually, while net income reached $1.41B with a 6.26% margin. Technical indicators show bearish momentum with key support at $61-62, though RSI levels remain neutral. The company continues expanding capacity to meet robust demand, with same-day delivery recently launched in Minneapolis.

CVNA presents growth potential with analyst consensus target of $84.07 (33% upside), but faces risks from high debt levels ($5.26B long-term) and volatile cash flow patterns. The stock's elevated P/E of 33.44 and EV/EBITDA of 507.31 suggest premium valuation, requiring sustained execution to justify. Competitive pressures in online auto retail and interest rate sensitivity remain key watchpoints for investors.

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.